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ABSTRACT
Chromatin immunoprecipitation (ChIP) studies were
conducted in human hepatocytes treated with
rifampicin in order to identify new pregnane-X
receptor (PXR) target genes. Genes, both previously
known to be involved and not known to be involved
in drug disposition, with PXR response elements
(PXREs) located upstream, within or downstream
from their potentially associated genes, were iden-
tified. Validation experiments identified several new
drug disposition genes with PXR binding sites.
Of these, only CYP4F12 demonstrated increased
binding in the presence of rifampicin. The role of
PXR in the basal and inductive response of
CYP4F12 was confirmed in hepatocytes in which
PXR was silenced. We also assessed the associa-
tion of PXR-coactivators and -corepressors with
known and newly identified PXREs. Both PXR and
the steroid receptor coactivator (SRC-1) were found
to bind to PXREs in the absence of rifampicin,
although binding was stronger after rifampicin treat-
ment. We observed promoter-dependent patterns
with respect to the binding of various coactivators
and corepressors involved in the regulation of
CYP4F12, CYP3A4, CYP2B6, UGT1A1 and P-glyco-
protein. In conclusion, our findings indicate that
PXR is involved in the regulation of CYP4F12 and
that PXR along with SRC1 binds to a broad range
of promoters but that many of these are not induci-
ble by rifampicin.
INTRODUCTION
The human pregnane-X receptor (PXR, NR1I2) is an
essential regulator of a large and growing array of drug
disposition genes which correspond to all phases of drug
metabolism. These include phase I enzymes such as cyto-
chrome P450 (CYP), phase II enzymes such as uridine-
50-diphosphate glucuronosyltransferases (UGTs) and
transporters such as the multidrug resistance protein
MDR1 P-glycoprotein (Pgp) (1). A large body of litera-
ture has revealed that PXR activation by xenobiotics, in
the liver and intestine, results in a signiﬁcant increase
in the expression of drug metabolizing enzymes and trans-
porters (1–5). In addition to increased gene expression,
PXR can repress gene expression (6), indicating
that gene regulation via PXR is complex. Although
PXR functions as a defense mechanism against toxic
insults, it also represents the molecular basis for pharma-
cokinetic drug–drug interactions. For example, if one drug
activates PXR, administration of this drug can promote
its own elimination (autoinduction) or the elimination of
other coadministered drugs that are metabolized and
eliminated by PXR-target gene products, thereby reducing
the eﬃcacy of drug therapies in patients on combination
therapy (7–9).
As a prototypical nuclear receptor, PXR has a DNA-
binding domain (DBD) at the N-terminus and a ligand-
binding domain (LBD) at the C-terminus. The DBD is
responsible for binding to regulatory DNA sequences
such as the AGGTCA-like direct repeats spaced by 3, 4
or 5 bases (DR3, DR4 and DR5), and the everted repeats
separated by 6 or 8 bases (ER6 and ER8) located in the
PXR target genes (10). The LBD is multifunctional in that
it is capable of ligand binding, dimerization, transcrip-
tional activation, and interactions with transcriptional
co-factors. The C-terminal helix termed AF-2 is responsi-
ble for transcriptional activation by recruiting coactivators
through conformational rearrangement, or gene repression
by interactions with transcriptional corepressors (7,11).
Understanding of coactivators and corepressors of PXR
in the expression of target genes is relatively limited.
Recently, Moore et al. (12) reviewed some of the key
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lation of drug metabolizing enzymes and transporters.
Small heterodimer partner (SHP/NC0B2) and nuclear
receptor corepressor 2 (NCoR2/SMRT) were identiﬁed
as corepressors, while steroid receptor coactivators 1
(SRC1/NCOA1) and 2 (SRC2/GRIP1), nuclear receptor
interacting protein 1 (NRIP1/RIP140), peroxisome
proliferator-activated receptor-gamma coactivator (PGC-
1), and Forkhead transcription factor FKHR (FOXO1)
were reported as coactivators.
While NCoR, SHP and SMRT are known to be core-
pressors of genes, studies undertaken by several groups
using transfection assays in CV1, HepG2, HEK293 and
yeast cells indicate that only SHP and SMRT are involved
in transcriptional repression of PXR (13–16). Ourlin et al.
(13) demonstrated in HepG2 cells that SHP blocks PXR
binding to DNA in a ligand-dependent manner. In addi-
tion, their studies using transient transfection assays
proved that increased expression of SHP resulted in a
decrease in PXR activation in the presence of rifampicin.
Tirona et al. (17) highlighted the critical involvement of
hepatocyte nuclear factor 4a (HNF4a), together with
PXR in the regulation of CYP3A4. Using mammalian
two-hybrid assays Li and Chiang (18) showed that
HNF4a and SHP compete to interact with PXR. These
studies also revealed that SHP only partially blocked the
PXR/SRC1 interaction and was unable to block the PXR/
PGC-1a interaction. Using chromatin immunoprecipita-
tion (ChIP) analysis, they observed that rifampicin
increased the recruitment of HNF4a and SRC1 to the
CYP3A4 chromatin but reduced PGC1a recruitment.
In most studies referenced above, cell lines in which
proteins were overexpressed were not of hepatic origin
and promoter elements were outside of their natural chro-
matin environment. In addition, to assess DNA–protein
and protein–protein interactions researchers used electro
mobility shift assays that make use of ‘naked’ DNA as a
probe, whereas in living cells much of the DNA is covered
by nucleosomes. Thus, many binding sites for a protein in
living cells could be masked by the presence of nucleo-
somes, but they would be scored as positive by the bio-
chemical assays (19).
The goals of the experiments presented in this manu-
script were 3-fold: First, using ChIP, we searched for new
PXR target genes in cryopreserved primary human hepa-
tocytes treated with rifampicin. Second, using ChIP-based
assays, we studied binding of PXR, as well as PXR-
corepressors and -coactivators to newly identiﬁed and
established PXR response elements (PXREs) before and
after treatment with rifampicin. Third, we investigated
whether newly identiﬁed genes in the ChIP experiments
were bona ﬁde PXR target genes by measuring mRNA
levels after small interfering RNA (siRNA)-mediated
knockdown of PXR.
MATERIALS AND METHODS
Materials
Cryopreserved human hepatocytes, antibiotic/
antimycotic Torpedo Mix, In VitroGRO-CP Media and
In VitroGRO-HI Incubation Media were purchased
from In Vitro Technologies (Baltimore, MD, USA).
Rifampicin, glycine, Igepal, phenylmethanesulfonyl
ﬂuoride (PMSF) and formaldehyde were purchased from
Sigma-Aldrich (St Louis, MO, USA). RNeasy 96 Kit was
purchased from Qiagen (Valencia, CA, USA). Anti-PXR
(sc-25381), -SRC-1 (sc-8995), -SRC-3 (sc-7216), -N-CoR
(sc-8994), -HNF4a (sc-8987), -GRIP-1 (sc-8996), -PGC-1a
(sc-13067), -SMRT (sc-1610), -FKHR (sc-11350), -RIP140
(sc-8997) and -SHP (sc-15283) antibodies were purchased
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA). Anti-RNA pol II (CTD phospho Ser-2, ab5095)
antibody was purchased from Abcam Inc. (Cambridge,
MA, USA). TaqMan Universal PCR Master Mix
was purchased from Applied Biosystems (Foster City,
CA, USA). Collagen-coated 6-well plates were pur-
chased from BD Biosciences (San Jose, CA, USA).
ON-TARGETplus GAPDH Control Pool siRNA
(D-001830), ON-TARGETplus Non-Targeting Pool
siRNA (D-001810), ON-TARGETplus SMARTpool
human NR1I2 siRNA (L-003415) and DharmaFECT-1
transfection reagent were purchased from Dharmacon
Inc. (Lafayette, CO, USA). All other reagents and chemi-
cals were of the highest grade and purchased from Fisher
Scientiﬁc (Pittsburg, PA, USA).
Cellculture anddrug treatment
Cryopreserved primary human hepatocytes from three dif-
ferent donors (LHO: 68-year-old female Caucasian; 455:
37-year-old female Caucasian; and DMQ: 59-year-old
African-American female) were used in our studies.
Hepatocytes were plated in 6-well collagen-coated plates
at a seeding density of 1.5 10
6 cells per well in In
VitroGRO-CP Media and 2.2% antibiotic/antimycotic
Torpedo Mix and placed in an incubator (378C, 5%
CO2). After 24h the plating medium was discarded and
hepatocytes were treated for 3h with either DMSO (0.1%)
or rifampicin 10mM, prepared in In VitroGRO-HI incu-
bation Media and 2.2% antibiotic/antimycotic Torpedo
Mix. Following the 3h incubation period, hepatocytes
were ﬁxed with 1/10 formaldehyde solution (11% formal-
dehyde, 0.1M NaCl, 1M EDTA, 50mM HEPES pH 7.9).
Fixation was stopped by adding 1/20 volume of glycine
solution (2.5M glycine, water) to the existing media. Cells
were washed, centrifuged (800g for 10min.) and resus-
pended in phosphate buﬀered saline (PBS)–Igepal solution
(0.5% Igepal in PBS). Thereafter, cells were centrifuged
(800g for 10min.) and again resuspended in PBS–Igepal to
which 100ml PMSF (100mM in ethanol) was added. Cells
were then centrifuged (800g for 10min.), pelleted and
snap-frozen on dry ice and stored at  808C for further
analysis.
ChIP-based assays
In order to identify PXREs present on genes in the entire
human genome, cross-linked chromatin from hepatocytes
treated with DMSO (0.1%) or 10mM rifampicin were
immunoprecipitated against a validated-PXR antibody.
Cloning, sequencing, analysis of tags and conﬁrmation
of the PXR-binding sites using polymerase chain reaction
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Data) targeting a region within 200bp of each selected
alignment were conducted as previously described (20).
Assays to conﬁrm that increased PXR-binding resulted
in increased transcription were undertaken by immuno-
precipitating cross-linked chromatin against RNA poly-
merase II (Pol II) antibody and the enrichment of Pol II
was determined by quantitative (q)-PCR (20). To assess
the involvement of coactivators and corepressors in the
PXR-regulation of CYP3A4, CYP2B6, CYP4F12,
UGT1A1 and MDR1 cross-linked chromatin was immu-
noprecipitated against the aforementioned coactivators
and corepressors and the enrichment of SRC-1, SRC-3,
GRIP1, NCOR, PGC1a, HNF4a, FKHR, RIP140,
SMRT and SHP were determined by q-PCR.
RNA interference
Cryopreserved human hepatocytes (120000 cells/well)
were cultured in antibiotic-free In VitroGRO-HI plating
medium in collagen-I coated 48-well plates. After
24h ON-TARGETplus SMARTpool human NR1I2
siRNA (L-003415) was used to knockdown PXR.
ON-TARGETplus GAPDH Control Pool siRNA
(D-001830) and ON-TARGETplus Non-Targeting Pool
siRNA (D-001810) were used as internal controls.
Brieﬂy, siRNA duplexes (100nmol/well) and
DharmaFect-1 (3ml/well) were diluted in 50ml antibiotic-
and serum-free In VitroGRO-HI incubation medium
separately and mixed gently and incubated for 5min at
room temperature. Afterward, PXR-siRNA and
DharmaFect-1 were mixed (total volume 100ml) and incu-
bated at room temperature for 20min. Then, 100ml
siRNA–DharmaFect-1 complex was diluted with 100ml
antibiotic-free medium and added to the well. Under
these conditions, the transfected cells looked morpholog-
ically normal after 72h, and they did not diﬀer from
untransfected cells in cell viability and levels of the 18S
mRNA housekeeping gene (data not shown). Thereafter,
hepatocytes were treated with 10mM rifampicin or 0.1%
DMSO (vehicle control) for 48h. To ensure that func-
tional and speciﬁc silencing was obtained, the mRNA
levels of PXR and known PXR target genes (CYP3A4,
CYP2B6, Pgp and UGT1A1) were compared between
PXR-siRNA and SCR (scrambled) siRNA groups
before and after treatments in all experiments.
Reverse-transcription Q-PCR
Total RNA was isolated using the RNeasy 96 Kit. A two-
step reverse transcriptase (RT)-PCR reaction was con-
ducted by reverse transcribing 50ng of total RNA to
cDNA using TaqMan Reverse Transcription Reagents,
according to the TaqMan Universal PCR Master Mix
protocol. PCR reactions were then prepared by adding
an aliquot of cDNA (3ml) to a reaction mixture containing
the TaqMan Fast Universal PXR Master Mix solution,
primers (Supplementary Table S1, Supplementary Data),
and probes for the speciﬁc gene targets. PCR-ampliﬁed
cDNAs were detected by real-time ﬂuorescence on an
ABI PRISM 7900 Fast Sequence Detection System
(Perkin Elmer, Wellesley, MA, USA). Gene expression
values were calculated based on the comparative Ct
method and normalized to values obtained for 18S ribo-
somal RNA.
Statistical analysis
The diﬀerences in PXR-, Pol II-, SRC-1-, SRC-3-,
GRIP1-, NCOR-, PGC1a-, HNF4a-, FKHR-, RIP140-,
SMRT- and SHP binding, between hepatocytes treated
with 10mM rifampicin or 0.1% DMSO (vehicle control)
were analyzed using the Student’s t-test. Statistical analy-
sis of the diﬀerences in mRNA gene expression was based
upon diﬀerences in the Ct values. Diﬀerences with
P-values <0.05 were considered signiﬁcant.
RESULTS
Identification ofnew PXR target genes
In order to identify new genes containing PXR binding
sites, we performed ChIP analyses with cryopreserved
human hepatocytes treated with the prototypical inducer
rifampicin (10mM, 3h). The batches of hepatocytes used
in these studies were selected for high inducibility of
CYP3A4 mRNA (45- to 75-fold relative to vehicle con-
trol) after treatment with rifampicin (10mM) for 48h (data
not shown). To validate the polyclonal anti-PXR antibody
used for ChIP, the ability to detect known PXR target
genes was determined (21): Enrichment of CYP3A4,
CYP2B6, UGT1A1 and MDR1 PXRE were 3.9-, 4.2-,
2.2- and 1.5-fold higher in rifampicin as opposed to vehicle
(control; 0.1% DMSO)-treated cells (Figure 1A).
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Figure 1. PXR (A) and SRC-1 (B) binding to several known PXRE-
containing promoters including CYP3A4, CYP2B6, UGT1A1, MDR1
and Untr 5 and 20. Cryopreserved human hepatocytes were treated
with vehicle (Control; 0.1% DMSO) or rifampicin (10mM) for 3h
and processed for ChIP assays as described in Materials and methods
section. Studies repeated with diﬀerent batches of hepatocytes yielded
similar results. The error bars represent the SD from the mean of trip-
licate assays of an individual experiment, n=3,
 P<0.05.
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detected in the absence of rifampicin (Figure 1A),
although binding was signiﬁcantly lower than that after
treatment with rifampicin. Measuring of PXR interaction
to two untranscribed regions (Untr) served as negative
controls. While ChIPs with a control IgG are often con-
ducted as a negative control, our ﬁndings (data not
shown) suggested that the values obtained using this
approach provided a less reliable baseline than assaying
negative control regions (Untr) with the experimental anti-
body. Also, we have observed that diﬀerent antibodies
have diﬀerent levels of background (20). Our unpublished
data also suggest that antibody titration experiments do
not necessarily show the expected concentration-
dependent increase and then plateau, but one continues
to see some increase (but not linear or proportional with
the antibody amount) upon increasing the antibody
amount. In our studies, we could not utilize much higher
antibody amounts which we believe were already in excess.
A discovery approach for the identiﬁcation of PXR
binding sites in the human genome was initiated (see
Materials and methods section). After chromatin precipi-
tation with the anti-PXR antibody,  7300 tags represent-
ing anti-PXR immunoprecipitated DNA, which were
derived from rifampicin-treated cells, was sequenced
(Figure 2). Approximately 5000 of these sequences pro-
duced acceptable genomic alignments from which
32.7% (or about 1/3) did not map within 10kb of any
gene. The number of genes that had at least one tag align-
ment within 10kb was 3745 (using the NCBI gene data-
base). Of these 3745 genes, 500 had two or more tag
alignments (Supplementary Table S2, Supplementary
Data). For these 500 genes, there were a total of 1244
aligns (within  10kb), of which 877 (70.5%) mapped
inside genes, 190 (15.3%) upstream and 177 (14.2%)
downstream. Our analysis included all of these tags since
PXRE sites may be important wherever they lie within the
gene and do not necessarily need to be located in the 50
UTR. Because ChIP fragments were <600bp, 1200 was
set as the maximal distance between two tags representing
the same binding site, such that  500 tags generated 182
clusters consisting of two or more distinct alignments
within 1200bp). Genes identiﬁed as known to contain
PXR binding sites in their promoter regions were
CYP3A4 and MDR1. As expected, the lack of identiﬁca-
tion of additional known PXR target genes indicated that
the screen had not reached saturation.
The binding of PXR to identiﬁed genomic locations in
cryopreserved hepatocytes treated with either vehicle or
rifampicin was conﬁrmed by q-PCR using PXR primers
encompassing  200nt of the putative PXR binding sites
(Supplementary Table S1, Supplementary Data). Of the
182 clusters, 12 clusters with strong PXR binding
(>5-fold binding relative to the negative control region)
were selected for further testing (Table 1). Several of these
were not in the proximity of genes known to be involved in
drug metabolism or transport but were involved in apop-
tosis, electron transport, hormone catabolic processes,
response to chemical stimuli and steroid, estradiol, linoleic
acid, retinol, tryptophan, arachidonic acid, fatty acid and
lipid metabolism. In addition, 29 tags were selected which
were in the proximity of genes known to be involved in
diﬀerent metabolic processes including drug metabolism,
or recently identiﬁed as PXR target genes by gene proﬁling
in studies with the colon carcinoma cell line LS180
(Table 1) (2). Of the 41 tags/clusters selected, 23 showed
elevated PXR binding (>5-fold increased binding com-
pared to the negative control regions) (Table 2).
Interestingly, of the 23 identiﬁed PXR-binding sites only
11 showed a trend towards increased PXR-binding in the
presence of rifampicin compared to the vehicle (Table 2
and Figure 3A). However, statistically signiﬁcant diﬀer-
ences were only observed for CYP4F12 and ABCC4.
In addition to assessing increased PXR-binding, we
also determined whether increased PXR binding at the
newly identiﬁed sites, as well as the previously identiﬁed
literature controls, did result in increased binding of
DNA-dependent RNA Pol II to these genes (Figure 4).
Determinations were performed in a ChIP-type assay
ChIP with anti-PXR antibody in hepatocytes treated
with rifampicin
Direct cloning
5 318 tags with 1-3 acceptable hit(s)
Filter
2 tags 1 200 bp apart = 182 clusters
Selection
12 clusters and 29 single tags selected for further
analysis
23 tags/clusters identified with strong (>5-fold) PXR-
binding sites
3 745 were <10 Kb from the TSS
500 with 2 or more tag alignments
7 332 clones sequenced
Q-PCR of selected genes
Figure 2. Construction of the PXR-binding site library. Outline of the
strategy for ChIP-cloning and ﬁltering of sequences. ‘Filter’: short
sequences (<40bp), highly repetitive sequences and those with <90%
identity to the genome were eliminated. ‘Selection’: 12 clusters with
strong PXR binding (>5-fold binding relative to the negative control
region) were selected for further testing. In addition, 29 tags were
selected which were in the proximity of genes known to be involved
in diﬀerent metabolic processes including drug metabolism, or recently
identiﬁed as PXR target genes by gene proﬁling in studies with the
colon carcinoma cell line LS180 (Table 1) (2).
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Genomic region Tag/Cluster name Gene/Proteome description
CYP3A4 (PXRE) Control (literature)
CYP2B6 Control (literature)
UGT1A1 Control (literature)
MDR1 Control (literature)
CARS GP0059_02_B04-frag008 Encodes a class 1 aminoacyl-tRNA synthetase, cysteinyl-tRNA synthetase. Each of the
20 aminoacyl-tRNA synthetases catalyzes the aminoacylation of a speciﬁc tRNA or
tRNA isoaccepting family with the cognate amino acid. Alterations in this region have
been associated with the Beckwith–Wiedemann syndrome, Wilms tumor, rhabdo-
myosarcoma, adrenocortical carcinoma, and lung, ovarian and breast cancer.
OSBP2 GP0059_06_B06-frag009 Oxysterols are byproducts of cholesterol that can have cytotoxic eﬀects on many cell
types. The membrane-bound protein encoded by this gene contains a pleckstrin
homology domain and an oxysterol-binding region. It binds oxysterols such as
7-ketocholesterol and may inhibit their cytotoxicity.
PFAS GP0059_03_A11-frag004 The enzyme encoded by this gene catalyzes the fourth step of inosine monophosphate
biosynthesis.
CD59 GP0059_06_C01-frag008 This gene encodes a cell surface glycoprotein that regulates complement-mediated cell
lysis, and it is involved in lymphocyte signal transduction. This protein is a potent
inhibitor of the complement membrane attack complex, whereby it binds complement
C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorpora-
tion of multiple copies of C9 into the complex, which is necessary for osmolytic pore
formation. This protein also plays a role in signal transduction pathways in the acti-
vation of T cells. Mutations in this gene cause CD59 deﬁciency, a disease resulting in
hemolytic anemia and thrombosis, and which causes cerebral infarction.
CEACAM6 GP0059_05_C06-frag011 Carcinoembryonic antigen is one of the most widely used tumor markers in serum
immunoassay determinations of carcinoma. An apparent lack of absolute cancer
speciﬁcity for CEA probably results in part from the presence in normal and neo-
plastic tissues of antigens that share antigenic determinants with the 180kDa form of
CEA.
DOCK1 GP0059_08_D04-frag004 Dedicator of cytokinesis 1, member of the CDM family, contains an SH3 domain,
binds phosphatidylinositol-3,4,5-triphosphate, integrin receptor-mediated complex
formation with BCAR1 and CRK leads to RAC1 activation and phagocytosis of
apoptotic cells.
FLJ10986 GP0059_06_D06-frag004
CYP4F12 Cluster 19153 (GP0059_07_F05-
frag007; GP0059_06_D09-frag005)
Cytochrome P450 family 4 subfamily F polypeptide 12, metabolizes arachidonic acid
by omega 3-hydroxylation, metabolizes docosahexanoic acid, docosapentaenoic acid,
leukotrienes and the antihistamine drug ebastine.
CYP3A5 GP0059_02_H05-frag007 This protein localizes to the endoplasmic reticulum and its expression is induced by
glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such
as nifedipine and cyclosporine as well as the steroid hormones testosterone, proges-
terone and androstenedione. This gene is part of a cluster of cytochrome P450 genes
on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very
similar to CYP3A5. This similarity has caused some diﬃculty in determining whether
cloned sequences represent the gene or the pseudogene.
CYP3A5P2/CYP3A4 Cluster 7170 (GP0059_04_A01-
frag006; GP0059_01_D05-frag007)
ABCC4 GP0059_10_C11-frag004 The protein encoded by this gene is a member of the superfamily of ATP-binding
cassette (ABC) transporters. This protein is a member of the MRP subfamily which is
involved in multi-drug resistance. The speciﬁc function of this protein has not yet been
determined; however, this protein may play a role in cellular detoxiﬁcation as a pump
for its substrate, organic anions.
SULT1B1 GP0059_01_B02-frag007 Sulfotransferase enzymes catalyze the sulfate conjugation of many hormones, neuro-
transmitters, drugs and xenobiotic compounds. These cytosolic enzymes are diﬀerent
in their tissue distributions and substrate speciﬁcities. The gene structure (number and
length of exons) is similar among family members.
SLC40A1 Cluster 2215 (GP0059_10_F11-
frag006; GP0059_01_C04-frag005)
Solute carrier family 40 (iron-regulated transporter) member 1, an iron transporter
involved in iron homeostasis and regulation of translation initiation, possibly involved
in development; gene mutations are a cause of autosomal dominant hemochromatosis.
KCNK5 Cluster 6129 (GP0059_03_F09-
frag006; GP0059_10_A04-frag005)
Potassium channel subfamily K member 5, mediates a pH and acid sensitive, non-
inactivating, outwardly rectifying K
+ conductance, involved in potassium ion trans-
port, inhibited by amide anesthetics.
UGT1A5 GP0059_07_C01-frag002 Encodes a UDP-glucuronosyltransferase, an enzyme of the glucuronidation pathway
that transforms small lipophilic molecules, such as steroids, bilirubin, hormones and
drugs, into water-soluble, excretable metabolites.
AKR1C1 GP0059_01_B10-frag003 Aldo-keto reductase family 1 member C1 acts in xenobiotic and progesterone meta-
bolism, increased expression is observed in lung cancer, glaucoma and polycystic ovary
syndrome.
(continued)
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Genomic region Tag/Cluster name Gene/Proteome description
AKR1C2 GP0059_02_C12-frag007 Aldo-keto reductase family 1 member C2 (dihydrodiol dehydrogenase), functions in
bile transport, steroid metabolism and xenobiotic metabolism, expression is decreased
in prostate and breast cancer but upregulated in esophageal squamous cell carcinoma.
CYP2C8 (gene) GP0059_03_D11-frag004 Cytochrome P450 family 2 subfamily C polypeptide 8, a member of heme-binding
mono-oxygenase superfamily, metabolizes steroids, fatty acids and xenobiotics, altered
expression may contribute to colon cancer development.
CYP2C8 (downstream) GP0059_05_C04-frag010
PAPSS2 GP0059_01_A08-frag002 30-phosphoadenosine 50-phosphosulfate synthase 2, involved in skeletal development;
mutation in the corresponding gene correlates with spondyloepimetaphyseal dysplasia,
mouse Papss2 gene is associated with brachymorphism.
HDAC7A GP0059_06_H02-frag002 Histone acetylation/deacetylation alters chromosome structure and aﬀects transcrip-
tion factor access to DNA. The protein encoded by this gene has sequence homology
to members of the histone deacetylase family. This gene is orthologous to mouse
HDAC7 gene whose protein promotes repression mediated via the transcriptional
corepressor SMRT.
TEAD2 GP0059_01_B06-frag007 TEA domain family member 2, a member of the TEA DNA-binding domain family of
transcription factors, regulates transcription, may be involved in organ morphogenesis
and central nervous system development.
HIST1H1E GP0059_06_E12-frag008 The linker histone, H1, interacts with linker DNA between nucleosomes and functions
in the compaction of chromatin into higher order structures. This gene is intronless
and encodes a member of the histone H1 family. Transcripts from this gene lack
polyA tails but instead contain a palindromic termination element. This gene is found
in the large histone gene cluster on chromosome 6.
BMP1 GP0059_06_G08-frag002 Encodes a protein that is capable of inducing formation of cartilage in vivo. Although
other bone morphogenetic proteins are members of the TGF-b superfamily, this gene
encodes a protein that is not closely related to other known growth factors.
CFL1 GP0059_09_F09-frag0005 Coﬁlin 1 (non-muscle), plays a role in actin ﬁlament depolymerization and lymphocyte
chemotaxis, involved in the G protein-coupled receptor protein and Rho protein sig-
naling pathways.
EIF5 GP0059_05_G08-frag003
TGIF2 GP0059_03_G06-frag003 This gene is a DNA-binding homeobox protein and a transcriptional repressor. The
encoded protein appears to repress transcription by recruiting histone deacetylases to
TGF-b-responsive genes. This gene is ampliﬁed and overexpressed in some ovarian
cancers, and mutations in this gene can cause holoprosencephaly.
BBC3 Cluster 19-76 Bcl-2 binding component 3, regulates p53 (TP53)-dependent and independent apop-
tosis, increased expression of BBC3 plays a role in chronic lymphocytic leukemia and
lung neoplasms and is used in the treatment of glioma and colorectal neoplasms.
CLG Cluster 19-185
GLDC Cluster 9-228 Glycine decarboxylase (glycine dehydrogenase, P-protein), part of the glycine cleavage
system that catalyzes the decarboxylation of glycine; mutation of the corresponding
gene causes nonketotic hyperglycinemia.
ABCB4 GP0059_06_D02-frag005 This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP
subfamily are involved in multidrug resistance as well as antigen presentation. This
gene encodes a full transporter and member of the P-glycoprotein family of membrane
proteins with phosphatidylcholine as its substrate. The function of this protein has not
yet been determined; however, it may involve transport of phospholipids from liver
hepatocytes into bile.
CENTD2 Cluster 11-186 Centaurin delta 2, functions as a GTPase activating protein (GAP) for both Arf and
Rho family proteins, mediates PIP3 phosphoinositide-dependent Golgi apparatus
membrane changes, ﬁlopodia formation and cell spreading.
ZNF281 Cluster 1-52 Zinc ﬁnger protein 281, a transcriptional repressor, member of the ZBP family, con-
tains four Kruppel-type zinc ﬁngers.
BCL9L Cluster 11-267 B-cell CLL/lymphoma 9-like, a BCL9-related protein that acts as a transcriptional
regulator, induces b-catenin (CTNNB1) nuclear translocation epithelial to mesenchy-
mal transition, enhances cell migration, expression is upregulated in colorectal tumors.
ARNT2 Cluster 15-179 Aryl-hydrocarbon receptor nuclear translocator 2, a protein that heterodimerizes with
HIF-1alpha (HIF1A) and is involved in hypoxia-induced erythropoietin (EPO)
expression.
ASS1 Cluster 9-86 The protein encoded by this gene catalyzes the penultimate step of the arginine bio-
synthetic pathway. There are approximately 10–14 copies of this gene including the
pseudogenes scattered across the human genome, among which the one located on
chromosome 9 appears to be the only functional gene for argininosuccinate synthetase.
Mutations in the chromosome 9 copy of ASS cause citrullinemia. Two transcript
variants encoding the same protein have been found for this gene.
CTNNA1 GF0059_10_B02-frag003
ELK1 GP0059_02_G12-frag003 This gene is a member of the Ets family of transcription factors and of the ternary
complex factor (TCF) subfamily. Proteins of the TCF subfamily form a ternary
complex by binding to the the serum response factor and the serum reponse element in
the promoter of the c-fos proto-oncogene. The protein encoded by this gene is a
nuclear target for the ras-raf-MAPK signaling cascade.
(continued)
Nucleic Acids Research,2009, Vol.37, No. 4 1165using an antibody against RNA Pol II (20). CYP4F12
showed a trend towards increased Pol II binding in the
presence of rifampicin. However, ABCC4, UGT1A5,
CARS, BMP1, TGIF2, BCL9L, CLG, GLDC and
ABCB4 showed no change. As expected, both CYP3A4
and CYP2B6 showed a  2-fold increase in binding of Pol
II (Figure 4). The increase observed for UGT1A1 and
MDR1 was not signiﬁcant.
In order to study the correlation between Pol II binding
by ChIP and mRNA levels, we also conducted quantita-
tive mRNA analysis using TaqMan following treatment of
hepatocytes with rifampicin for 3 or 48h (Figure 5). While
increases in mRNA expression were observed as early as
3h, the expression was signiﬁcantly higher after 48h of
drug treatment. CYP3A4, CYP2B6, CYP4F12, MDR1
and UGT1A1 demonstrated 4.8-, 5.6-, 1.9-, 2.7- and
2.1-fold higher levels of mRNA expression after 48h com-
pared to 3h drug treatment. Diﬀerences in mRNA levels
between genes did not correlate with the Pol II ChIP
experiments. The antibody used in these analyses is
against phospho-Ser 2 in the C-terminal domain of Pol
II, which is the elongating form of the polymerase. The
analysis was not done at the transcription start site of the
genes of interest as it is known that Pol II may be bound at
that area but not transcribing (22). Interestingly, the rela-
tive diﬀerence in mRNA accumulation after 3 and 48h of
treatment were most pronounced for CYP3A4 and
CYP2B6.
PXR knockdownin human hepatocytes
We conducted siRNA studies to further discern the invol-
vement of PXR in the regulation of CYP4F12, UGT1A5,
ABCB4 and ABCC4 which were identiﬁed as having
strong PXR binding sites using ChIP analysis. We
observed 79% knockdown in PXR mRNA levels in hepa-
tocytes transfected for 72h with PXR-siRNA relative to
hepatocytes that were transfected with SCR-siRNA (data
not shown). The basal expression levels of known PXR
target genes, such as CYP3A4, CYP2B6, MDR1 and
UGT1A1 were signiﬁcantly lower (54–97%) in hepatocytes
in which PXR was knocked down using PXR-siRNA
compared to non-speciﬁc SCR-siRNA (Figure 6A). A sta-
tistically signiﬁcant ( 80%, P<0.05) decrease was also
observed in the basal expression of CYP4F12. While
 30% decrease was observed in the basal expression of
UGT1A5, this was not statistically signiﬁcant when com-
pared to hepatocytes transfected with the non-speciﬁc
SCR-siRNA. To conﬁrm the speciﬁcity of the PXR-
siRNA we also determined whether basal expression
levels of the housekeeping genes 18S and GAPDH were
aﬀected. We did not observe a statistically signiﬁcant
decrease in the expression of these genes (data not
shown) following PXR-siRNA transfection.
A comparison of fold changes in gene expression in
hepatocytes transfected with either SCR-siRNA or
PXR-siRNA demonstrated a statistically signiﬁcant
decrease in the inductive response of CYP3A4 and
CYP2B6 when treated with the prototypical PXR activa-
tor rifampicin (Figure 6B). We also observed a statistically
signiﬁcant decrease in the inductive response of CYP4F12
in hepatocytes transfected with SCR-siRNA or PXR-
siRNA following treatment with rifampicin. No signiﬁ-
cant diﬀerence was observed in the expression of
UGT1A1, MDR1, UGT1A5, ABCB4 and ABCC4 in
SCR- versus PXR-transfected siRNA. The inductive
response that we observed for UGT1A5, ABCB4 and
ABCC4 in rifampicin-treated hepatocytes transfected
with SCR-siRNA relative to DMSO control without sub-
sequent knockdown in PXR-siRNA-transfected hepato-
cytes may be related to the regulation of these genes by
other transcription factors, such as the vitamin-D receptor
(VDR), farsenoid-X receptor (FXR) and aryl hydrocar-
bon receptor (AHR) (23–25).
Association of corepressors andcoactivators withPXR
binding sites
It was previously demonstrated that the steroid receptor
complex protein SRC1 associates with PXR after ligand
binding (26). Using a similar approach as used to deter-
mine PXR-binding to PXR gene promoters, we assessed
whether the level of binding of SRC1 was increased after
the treatment of cells with rifampicin. A very similar bind-
ing pattern to that observed with the anti-PXR antibody
was observed in which increased binding was found for all
four genes analyzed (Figure 1B). In addition, we assessed
the association of SRC1 with the 11 genes showing
Table 1. Continued
Genomic region Tag/Cluster name Gene/Proteome description
MTL5 GP0059_04_G12-frag010 Metallothionein proteins are highly conserved low-molecular-weight cysteine-rich
proteins that are induced by and bind to heavy metal ions and have no enzymatic
activity. They may play a central role in the regulation of cell growth and diﬀerenti-
ation and are involved in spermatogenesis. This gene encodes a metallothionein-like
protein which has been shown to be expressed diﬀerentially in mouse testes and ovary.
WT GP0059_05_B10-frag005
XRCC5 GP0059_01_D07-frag005 The protein encoded by this gene is the 80kDa subunit of the Ku heterodimer protein
which is also known as ATP-dependant DNA helicase II or DNA repair protein
XRCC5. Ku is the DNA-binding component of the DNA-dependent protein kinase,
and it functions together with the DNA ligase IV-XRCC4 complex in the repair of
DNA double-strand break by non-homologous end joining and the completion of
V(D)J recombination events.
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Nucleic Acids Research,2009, Vol.37, No. 4 1167increased binding to PXR after exposing the cells to rifam-
picin (Table 2). Again, binding patterns were very similar
to those found for PXR (Figure 3B). In most cases, lower
binding was detectable in cells not treated with rifampicin.
Of the 11 genes tested, only CYP4F12 demonstrated sig-
niﬁcantly increased binding for both PXR and SRC1 after
rifampicin treatment in three batches of hepatocytes.
We extended our studies to assess the involvement of
other previously published coactivators and corepressors
of PXR on the regulation of CYP3A4, CYP2B6,
CYP4F12, UGT1A1 and MDR1. ChIP analysis was per-
formed with antibodies speciﬁc for the coactivators
GRIP1, SRC3, PGC1a, FKHR and RIP140, and the cor-
epressors NCoR, SMRT and SHP. All antibodies used
have been evaluated by others before (see Material and
methods section) and speciﬁcity was conﬁrmed using
known target genes (data not shown).
Compared to the coactivators and corepressors that we
assessed, HNF4a showed a signiﬁcantly higher binding to
the promoter elements of CYP3A4, CYP2B6, CYP4F12,
UGT1A1 and MDR1 (Figures 7 and 8), but no increased
binding of HNF4a was detectable after treatment of cells
with rifampicin. In fact, the converse was true in that of
the ﬁve genes evaluated, two (CYP3A4 and CYP4F12)
showed a signiﬁcantly decreased binding in the presence
of rifampicin (Figure 7).
None of the other coactivators that we assessed showed
a statistically signiﬁcant increase in binding in cells treated
with rifampicin versus vehicle control. Interestingly,
GRIP1 showed a decrease in binding to CYP4F12 in the
presence of rifampicin. Of the corepressors tested, while a
trend towards decreased binding of SHP was observed for
CYP3A4 (Figure 8A), CYP2B6 (Figure 8B) and UGT1A1
(Figure 8D), we observed a statistically signiﬁcant
decrease only for MDR1 (Figure 8C).
DISCUSSION
Here we report the identiﬁcation of new genes containing
PXR binding sites using ChIP-based assays in cryopre-
served primary human hepatocytes. The use of ChIP can
detect the direct association of PXR and coactivators/cor-
epressors with promoter elements. This is diﬀerent from
gene proﬁling experiments with cells treated with PXR-
activators where it cannot be excluded that the induction
of genes is a secondary eﬀect of PXR activation. Our
studies indicate that PXR binds to PXREs in the presence
and absence of rifampicin, and that binding of PXR to
many of the newly identiﬁed genes does not increase after
treatment with rifampicin. The ability of PXR to regulate
the basal expression and inducibility of one of these new
genes, CYP4F12, was conﬁrmed by hepatocytes depleted
of PXR by siRNA. Finally, we extended our studies and
also found that binding of SRC1 correlates with transcrip-
tional activation of PXR target genes, whereas this was
not found for other coactivators or corepressors studied.
Using a ChIP-based discovery approach, we were able
to identify genes containing PXR binding sites which were
mapped against the entire human genome (Supplementary
Table S2, Supplementary data). Tags were identiﬁed
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1168 Nucleic Acids Research, 2009, Vol. 37,No. 4which were localized large distances upstream from,
within or downstream of their potentially associated
genes. The identiﬁed tags were located on all 23 chromo-
somes and included drug metabolizing and transporter
genes as well as genes not involved in drug disposition.
The presence of PXR-binding sites on genes not involved
in drug disposition is not unexpected given that recent
evidence suggests that PXR plays a role in hepatic lipid
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Nucleic Acids Research,2009, Vol.37, No. 4 1169metabolism (27). For instance, PXR binds to FOXA2
(Supplementary Table S2, Supplementary Data) and
represses its’ activity and the genes encoding the key
enzymes in energy metabolism. Furthermore, Dai et al.
(28) observed that ACC1 (Acetyl CoA carboxylase 1),
which is a lipogenic enzyme, was consistently lower in
PXR-null mice than wild-type mice. Their data indicated
that PXR is involved in the regulation of ACC-1 gene
expression during liver regeneration.
Using the data obtained in the ChIP-based discovery
approach we were able to conﬁrm that several previously
unidentiﬁed drug disposition genes contain PXREs
(Table 2). These included phase I (CYP4F12) and phase
II (SULT1B1 and UGT1A5) drug metabolizing enzymes,
as well as transporters (SLC40A1 and ABCB4).
In addition, our data also conﬁrmed previous studies
which indicated that CYP3A5, CYP2C8 and GSTT1
were PXR-target genes (Table 2) (1,2,29). Similar to
what we observed for the genes with known PXR-binding
sites (Figure 1A), PXR binding to the PXREs on 11 genes
analyzed in Figure 3A also occurred in the absence of
rifampicin. To ensure that our ﬁndings were not due to
the high inducibility of PXR in the cells we used in our
experiments, we have looked at binding to several targets
in two to three batches of hepatocytes. The data indicated
that results were consistently in agreement. While our dis-
covery approach identiﬁed many new genes binding to
PXR, the number of tags sequenced likely did not reach
saturation, and therefore more PXR target genes may be
identiﬁed in the future.
As expected, in our PXR antibody validation studies
with known PXR-binding sites, all four genes showed sig-
niﬁcantly higher PXR binding than was observed for the
control regions (Figure 1A). Similar to what we observed
during the discovery approach, binding of PXR to these
PXREs was also detected in the absence of rifampicin in
which the binding to MDR1 was much higher than that to
UGT1A1, CYP2B6 and CYP3A4. Our PXR knockdown
studies add additional evidence of PXR binding to PXREs
in the absence of ligand and the subsequent reduction in
the basal expression of CYP3A4, CYP2B6, UGT1A1, Pgp
and CYP4F12 (Figure 6). This is in line with ﬁndings by
Squires et al. (30) that PXR was present in the nucleus of
mouse liver cells prior to the addition of a ligand.
Similarly, in primary human hepatocytes in which PXR
was knocked down using the hPXR-siRNA–adenovirus
expression system, Kojima et al. (31) observed a reduction
in the basal expression of CYP3A4 and CYP2B6 mRNA
levels.
Our studies did conﬁrm that addition of rifampicin sig-
niﬁcantly increased the binding of PXR to the PXREs of
CYP3A4, MDR1, UGT1A1 and CYP2B6. Interestingly,
the fold increase of PXR binding to PXRE was several-
fold higher for CYP3A4 than was observed for MDR1
(Figure 1A). This may explain why minimal induction of
MDR1 was observed after treatment with rifampicin com-
pared to CYP3A4 (Figure 5). Also of interest was the
ﬁnding that PXR binding to PXREs did not always sig-
niﬁcantly increase in the presence of rifampicin (Figure 3)
which subsequently did not result in an increase in gene
transcription (Figure 4). This phenomenon is diﬃcult to
explain and could be related to the fact that PXR binding
to PXREs occurs in the absence of the ligand which could
lead to saturation of PXREs on speciﬁc genes (30). It
should also be noted that PXR binding to PXREs is not
the only determinant of an increase in gene transcription
but involves numerous corepressors and coactivators (12).
Using ChIP we identiﬁed CYP4F12 as having PXR-
binding sites. We conﬁrmed the involvement of PXR in
the regulation of CYP4F12 by assessing its’ basal expres-
sion and inducibility in human hepatocytes in which PXR
was knocked down. CYP4F12 mRNA has been detected
in several major tissues involved in drug disposition
ABCC4
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experiment, n=3,
 P<0.05.
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1170 Nucleic Acids Research, 2009, Vol. 37,No. 4including the liver, kidney and small intestine (32,33). It is
the only member of the CYP4F family involved in xeno-
biotic metabolism. In particular, CYP4F12 has been
shown to be highly eﬃcient toward metabolism of anti-
histaminic compounds, such as ebastine and terfenadine
(32,34,35). In addition to xenobiotics, CYP4F12 is also
involved in the oxidation of arachadonic acid and stable
prostaglandin H2 (PGH2) analogs (32,34).
Previous studies have highlighted the importance of the
coactivator SRC-1 in PXR activation and the subsequent
increase in gene transcription (36). Our studies conﬁrmed
that the SRC-1 binding pattern mirrors that observed with
PXR (Figures 1B and 3B). Similar to PXR, SRC-1 bind-
ing was increased after treatment of hepatocytes with
rifampicin. This is in line with crystallographic studies
which demonstrated that SRC-1 binds to PXR and stabil-
izes the PXR-LBD and together with the ligand exerts an
additive eﬀect on the stability of the receptor (36). Binding
of SRC-1 to the surface of PXR limits the ability of the
receptor to continuously change its conformation and
helps trap a single, active conformation of the ligand.
In addition to SRC-1, several other PXR-coactivators
and -corepressors have been implicated in PXR-mediated
gene regulation. These include the coactivators GRIP1,
PGC1a, FKHR and RIP140, and the corepressors
SMRT and SHP (12). Analysis of these coactivators and
corepressors did, in most cases, show signiﬁcant binding
to the promoter elements of the target genes in the absence
of rifampicin compared to the control Untr (Figure 8).
Treatment of the hepatocytes with rifampicin did not
result in a consistent increase in binding in the case of
coactivators or decreased binding in the presence of cor-
epressors. This may be related to our studies being con-
ducted in human hepatocytes and not in a recombinant
in vitro system. In comparison, studies by others were
conducted in cell lines in which proteins were overex-
pressed and were outside their natural chromatin environ-
ment (13–16). Overall, however, our data suggests that
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Nucleic Acids Research,2009, Vol.37, No. 4 1171binding of the coactivators and corepressors studied were
involved in the regulation of gene expression as binding
was higher than to the negative control and, with few
exceptions, the overall pattern of binding to the various
promoter elements studied were similar. An important
point to consider is that all our analyses were done after
treatment of hepatocytes with rifampicin and we cannot
exclude that diﬀerent binding behavior could be found in
the presence of other PXR activators.
HNF4a has been shown to cooperate at the  7.8kb
XREM in the PXR-dependent induction of CYP3A4
expression (17). Even though HNF4a binding was detect-
able in the presence and absence of rifampicin, it was
unexpected that we observed a decrease in binding of
HNF4a in the presence of rifampicin (Figure 7). The
role of HNF4a in PXR-mediated gene activation is not
clear as Li and Chiang (18) and Tegude et al. (37) have
shown that binding of HNF4a to the XREM-DR1 ele-
ment is not required for gene activation of the CYP3A4
promoter. This was conﬁrmed in a study by Kamiyama
et al. (38) in which HNF4a was knocked down using an
adenovirus expressing system in human hepatocytes. They
observed that hHNF4a-siRNA did not signiﬁcantly aﬀect
the fold-induction of CYP2B6, CYP2C8, CYP2C9 or
CYP3A4 mRNA levels following treatment with CYP
inducers, such as phenobarbital, rifampicin and dexa-
methasone. There is strong evidence, however, that
HNF4a is involved in regulating basal expression of
CYP3A4 (37,38).
In conclusion, in cryopreserved primary human hepato-
cytes we identiﬁed several new genes containing PXR
binding sites. We conﬁrmed the involvement of PXR in
the regulation of CYP4F12 using siRNA. We also found
that the SRC-1 binding pattern is very similar to PXR and
that both bind to promoter elements in the absence of
ligand. Finally, we did not observe a pattern correlating
with rifampicin treatment with respect to other PXR coac-
tivators/corepressors involved in gene regulation in the
presence of rifampicin.
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